To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.

Inclusion Criteria: * Those who are briefed about the clinical trial objectives and methods, and express their consent to participate in the trial by signing a written consent on the use of their personal information. * Patients diagnosed with essential hypertension and primary hypercholesterolemia. * Patients scheduled to receive either fimasartan plus atorvastatin or fimasartan plus atorvastatin plus ezetimibe. Exclusion Criteria: * Patients who received concomitant administration of fimasartan and atorvastatin within 4 weeks prior to baseline. * Patients with any contraindication to fimasartan, atorvastatin, or ezetimibe as specified in the approved product labeling. * Patients who have received investigational or study drugs from another clinical trial or research study within 12 weeks prior to baseline. However, participation in non-interventional observational studies is permitted. * Patients considered unsuitable for study participation at the discretion of the principal investigator or sub-investigator.